Compile Data Set for Download or QSAR
maximum 50k data
Found 50 with Last Name = 'ripka' and Initial = 'as'
TargetRhizopuspepsin(Rhizopus microsporus var. chinensis)
University Of Wisconsin-Madison

Curated by ChEMBL
LigandPNGBDBM50070005(((3R,6R,15R)-15-Hydroxymethyl-3-isopropyl-2,5-diox...)
Affinity DataKi:  1.30nMAssay Description:Compound was evaluated for potency towards nicotinic acetylcholine receptor in rat P2 brain membranes using [3H]-nicotine as a radioligandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRhizopuspepsin(Rhizopus microsporus var. chinensis)
University Of Wisconsin-Madison

Curated by ChEMBL
LigandPNGBDBM50070006(((Z)-(3R,6R,15R)-15-Hydroxymethyl-3-isopropyl-2,5-...)
Affinity DataKi:  336nMAssay Description:Compound was evaluated for inhibitory activity towards nicotinic acetylcholine receptor in rat P2 brain membranes using [3H]-nicotine as a radioligan...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190579(US9181219, 20)
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190585(US9181219, 2-{[3-fluoro-5-(trifluoromethyl)pyridin...)
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190585(US9181219, 2-{[3-fluoro-5-(trifluoromethyl)pyridin...)
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190576(US9181219, 6)
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190583(US9181219, 10)
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190593(US9181219, 2-[(4,5-dimethylpyridin-2-yl)sulfanyl]-...)
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190593(US9181219, 2-[(4,5-dimethylpyridin-2-yl)sulfanyl]-...)
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190588(US9181219, 2-[(3,5-dichloropyridin-2-yl)sulfanyl]-...)
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190588(US9181219, 2-[(3,5-dichloropyridin-2-yl)sulfanyl]-...)
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190586(US9181219, 2-[(5-bromopyridin-2-yl)sulfanyl]-1-(8-...)
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190578(US9181219, 16)
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190576(US9181219, 6)
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190591(US9181219, 2-[(3-chloropyridin-2-yl)sulfanyl]-1-(8...)
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190590(US9181219, 2-{[2-(8-methyl-1,2,3,4-tetrahydroquino...)
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190586(US9181219, 2-[(5-bromopyridin-2-yl)sulfanyl]-1-(8-...)
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190583(US9181219, 10)
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190578(US9181219, 16)
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190591(US9181219, 2-[(3-chloropyridin-2-yl)sulfanyl]-1-(8...)
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190592(US9181219, 2-[(3,4-dimethylpyridin-2-yl)sulfanyl]-...)
Affinity DataIC50: <1.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190581(US9181219, 8)
Affinity DataIC50: <1.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190575(US9181219, 1-(1,2,3,4-tetrahydroquinolin-1-yl)-2-{...)
Affinity DataIC50: <1.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190579(US9181219, 20)
Affinity DataIC50: <1.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190590(US9181219, 2-{[2-(8-methyl-1,2,3,4-tetrahydroquino...)
Affinity DataIC50: <1.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190584(US9181219, 6-{[2-(8-methyl-1,2,3,4-tetrahydroquino...)
Affinity DataIC50: <5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190578(US9181219, 16)
Affinity DataIC50: >5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190587(US9181219, methyl 5-chloro-6-{[2-(8-methyl-1,2,3,4...)
Affinity DataIC50: <5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190580(US9181219, 12)
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190587(US9181219, methyl 5-chloro-6-{[2-(8-methyl-1,2,3,4...)
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190577(US9181219, 21)
Affinity DataIC50: <5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190575(US9181219, 1-(1,2,3,4-tetrahydroquinolin-1-yl)-2-{...)
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190592(US9181219, 2-[(3,4-dimethylpyridin-2-yl)sulfanyl]-...)
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190582(US9181219, 24)
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190581(US9181219, 8)
Affinity DataIC50: <5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190577(US9181219, 21)
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190594(US9181219, 2-{[3-ethyl-5-(trifluoromethyl)pyridin-...)
Affinity DataIC50: <5.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190594(US9181219, 2-{[3-ethyl-5-(trifluoromethyl)pyridin-...)
Affinity DataIC50: <5.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190579(US9181219, 20)
Affinity DataIC50: >1.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190582(US9181219, 24)
Affinity DataIC50: <1.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190580(US9181219, 12)
Affinity DataIC50: <1.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190589(US9181219, 2-{[2-(8-methyl-1,2,3,4-tetrahydroquino...)
Affinity DataIC50: <1.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190589(US9181219, 2-{[2-(8-methyl-1,2,3,4-tetrahydroquino...)
Affinity DataIC50: <1.00E+4nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190584(US9181219, 6-{[2-(8-methyl-1,2,3,4-tetrahydroquino...)
Affinity DataIC50: <1.00E+4nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190576(US9181219, 6)
Affinity DataIC50: >2.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSodium channel protein type 2 subunit alpha(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190579(US9181219, 20)
Affinity DataIC50: >3.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190576(US9181219, 6)
Affinity DataIC50: >3.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSodium channel protein type 2 subunit alpha(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190578(US9181219, 16)
Affinity DataIC50: >3.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSodium channel protein type 2 subunit alpha(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190576(US9181219, 6)
Affinity DataIC50: >3.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSodium channel protein type 2 subunit alpha(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190575(US9181219, 1-(1,2,3,4-tetrahydroquinolin-1-yl)-2-{...)
Affinity DataIC50: >3.00E+4nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent